How to buy Anebulo Pharmaceuticals stock (Anebulo Pharmaceuticals)

Anebulo Pharmaceuticals is a biotechnology business based in the US. Anebulo Pharmaceuticals shares (ANEB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.70 – an increase of 71.72% over the previous week. Anebulo Pharmaceuticals employs 2 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Anebulo Pharmaceuticals stock

Buy Anebulo Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Anebulo Pharmaceuticals stock price (NASDAQ: ANEB)

Use our graph to track the performance of ANEB stocks over time.

Anebulo Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-22.

Latest market close	$1.70
52-week range	$0.80 - $3.30
50-day moving average more info button	$1.93
200-day moving average more info button	$2.33
Wall St. target price	$6.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.32

Is it a good time to buy Anebulo Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Anebulo Pharmaceuticals price performance over time

Historical closes compared with the close of $1.62 from 2024-12-26

1 week (2024-12-20)	63.64%
1 month (2024-11-27)	13.29%
3 months (2024-09-27)	-20.98%
6 months (2024-06-28)	-40.66%

1 year (2023-12-28)	-36.22%
2 years (2022-12-28)	-35.71%
3 years (2021-12-28)	6.5
5 years (2019-12-24)	N/A

Anebulo Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-65.97%
Return on equity TTM	-113.8%
Profit margin	0%
Book value	$0.15
Market Capitalization more info button	$42.8 million

TTM: trailing 12 months

Anebulo Pharmaceuticals share dividends

We're not expecting Anebulo Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

• Pfizer (PFE.US) (6.53% forward annual dividend yield)
• AstraZeneca PLC ADR (AZN.US) (2.27% forward annual dividend yield)
• AbbVie (ABBV.US) (3.74% forward annual dividend yield)

Anebulo Pharmaceuticals share price volatility

Over the last 12 months, Anebulo Pharmaceuticals's shares have ranged in value from as little as $0.8001 up to $3.3. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anebulo Pharmaceuticals's is -1.01. This would suggest that Anebulo Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Anebulo Pharmaceuticals has bucked the trend.

To put Anebulo Pharmaceuticals's beta into context you can compare it against those of similar companies.

• Pfizer (PFE.US): 0.615
• AstraZeneca PLC ADR (AZN.US): 0.18
• AbbVie (ABBV.US): 0.613

Anebulo Pharmaceuticals overview

Anebulo Pharmaceuticals, Inc. , a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas. .

Frequently asked questions

null
What percentage of Anebulo Pharmaceuticals is owned by insiders or institutions?
Currently 64.221% of Anebulo Pharmaceuticals shares are held by insiders and 28.176% by institutions. How many people work for Anebulo Pharmaceuticals?
Latest data suggests 2 work at Anebulo Pharmaceuticals. When does the fiscal year end for Anebulo Pharmaceuticals?
Anebulo Pharmaceuticals's fiscal year ends in June. Where is Anebulo Pharmaceuticals based?
Anebulo Pharmaceuticals's address is: 1017 Ranch Road 620 South, Lakeway, TX, United States, 78734 What is Anebulo Pharmaceuticals's ISIN number?
Anebulo Pharmaceuticals's international securities identification number is: US0345691036